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Abbreviations used in this paper: ALT, alanine aminotransferase; CAR,
chimeric antigen receptor; cccDNA, covalently closed circular DNA; CEA,
carcinoembryonic antigen; DC, dendritic cells; HBsAg, hepatitis B sur-
face antigen; HBV, hepatitis B virus; HBVtg, hepatitis B virus transgenic;
HCC, hepatocellular carcinoma; IFN, interferon; IL, interleukin; S-CAR,
hepatitis B virus–specific chimeric antigen receptor; scFv, single-chain
fragment variable; TNF, tumor necrosis factor.BACKGROUND & AIMS: Antiviral agents suppress
hepatitis B virus (HBV) replication but do not clear the
infection. A strong effector T-cell response is required to
eradicate HBV, but this does not occur in patients with
chronic infection. T cells might be directed toward virus-
infected cells by expressing HBV-specific receptors and
thereby clear HBV and help to prevent development of
liver cancer. In mice, we studied whether redirected T cells
can engraft after adoptive transfer, without prior T-cell
depletion, and whether the large amounts of circulating
viral antigens inactivate the transferred T cells or lead
to uncontrolled immune-mediated damage. METHODS:
CD8þ T cells were isolated from mice and stimulated
using an optimized protocol. Chimeric antigen receptors
(CARs) that bind HBV envelope proteins (S-CAR) and
activate T cells were expressed on the surface of cells using
retroviral vectors. S-CAR–expressing CD8þ T cells, which
carried the marker CD45.1, were injected into CD45.2þ
HBV transgenic mice. We compared these mice with mice
that received CD8þ T cells induced by vaccination, cells
that express a CAR without a proper signaling domain, or
cells that express a CAR that does not bind HBV proteins
(controls). RESULTS: CD8þ T cells that expressed HBV-
specific CARs recognized different HBV subtypes and
were able to engraft and expand in immune-competent
HBV transgenic mice. After adoptive transfer, the
S-CAR–expressing T cells localized to and functioned in
the liver and rapidly and efficiently controlled HBV
replication compared with controls, causing only transient
liver damage. The large amount of circulating viral antigen
did not impair or overactivate the S-CAR–grafted T cells.
CONCLUSIONS: T cells with a CAR specific for HBV
envelope proteins localize to the liver in mice to reduce
HBV replication, causing only transient liver damage.
This immune cell therapy might be developed for
patients with chronic hepatitis B, regardless of their
HLA type.
Keywords: Immunotherapy; Chronic Hepatitis B; Hepato-
cellular Carcinoma; Adoptive T-Cell Therapy.
atients chronically infected with hepatitis B virus© 2013 by the AGA Institute
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http://dx.doi.org/10.1053/j.gastro.2013.04.047P(HBV) are at high risk for developing cirrhosis and
hepatocellular carcinoma (HCC), which lead to more than
0.5 million deaths per year.1 Antiviral nucleos(t)ideanalogues control but do not eradicate the virus because
they do not target the nuclear persistence form of the
virus, the covalently closed circular DNA (cccDNA).2 The
episomal HBV cccDNA serves as a transcription template
and can cause a relapse of hepatitis B when pharmaco-
logical treatment ends.3,4 During acute, self-limited hep-
atitis B, patients mount a strong T-cell response against
multiple viral antigens5–8 that is required to eliminate
cccDNA-positive hepatocytes and to clear the virus.9 Such
a T-cell response is lacking in chronic infection.
The aim of immunotherapy against chronic hepatitis
B is to restore efficient antiviral immune responses and
complement pharmacological antiviral therapy to elimi-
nate remaining infected cells. A promising immunother-
apeutic approach is the adoptive transfer of genetically
modified HBV-specific T cells. In infected cells, HBV en-
velope proteins are incorporated into endoplasmic retic-
ulum membranes, where they either form (sub)viral
particles or may reach the cell surface by physiological
membrane exchange.10 These (sub)viral particles can be
detected in large amounts in sera of infected patients
as hepatitis B surface antigen (HBsAg) and very likely
contribute to induction of immune tolerance.11 Because
the expression of HBV surface proteins is not controlled
by available antiviral agents and is usually maintained in
HCC with integrated viral genomes, HBsAg remains pos-
itive under antiviral therapy, even in late stages of chronic
hepatitis B in which HCC has developed. Targeting HBV
surface proteins therefore seems most promising.
We have previously shown that expression of a chimeric
antigen receptor (CAR) directed against the HBV surface
proteins enables human T cells to kill HBV-infected
human hepatocytes and to eliminate viral cccDNA
in vitro.12 On this basis, we here addressed the question
August 2013 T–CELL THERAPY FOR CHRONIC HEPATITIS B 457whether CAR-grafted, adoptively transferred T cells would
retain their function in vivo and control virus replication
without significant T cell–related toxicity in a model of
persistent HBV infection in HBV transgenic (HBVtg) mice
with a functional immune system.Materials and Methods
Mice
C57BL/6 (CD45.1þ) and HBVtg HBV1.3xfs mice (HBV
genotype D, serotype ayw13, CD45.2þ) were bred in specific
pathogen–free animal facilities. The study was conducted ac-
cording to the German Law for the Protection of Animals.Retroviral TransductionB
A
SI
C
A
N
D
TR
A
N
SL
A
TI
O
N
A
L
LI
V
ERCAR transgenes12 were cloned into the retroviral vector
MP71.14 Plasmids were amplified using Stbl3 bacteria (Life
Technologies, Darmstadt, Germany) and purified with a Mid-
iprep Plasmid DNA Endotoxin-free Kit (Sigma-Aldrich, Tauf-
kirchen, Germany). The packaging cell line Platinum-E15 was
transfected in a 6-well plate with 4 mg of plasmid DNA and 10 mL
of Lipofectamine 2000 (Life Technologies). After 16 hours, the
medium was replaced with 1.5 mL of T-cell medium. After 24
and 48 hours, the retrovirus supernatant was collected and
filtered through a 0.45-mm filter. Splenocytes were isolated from
CD45.1þ C57BL/6 mice after lysis of red blood cells.
For in vitro assays, splenocytes were stimulated overnight at a
density of 3  106 cells/mL with 10 ng/mL interleukin (IL)-2
(R&D Biosystems, Wiesbaden, Germany), 2 mg/mL anti-CD3,
and 0.1 mg/mL anti-CD28 antibody (kindly provided by
E. Kremmer, Helmholtz Zentrum München) and spinoculated
on RetroNectin-coated plates (12.5 mg/mL; TaKaRa Bio Europe
SAS, St. Germain en Laye, France) at 850g for 90 minutes at 32C
with retrovirus supernatant supplemented with IL-2 and
4 mg/mL protamine sulfate (Sigma-Aldrich).
For in vivo studies, CD8þ T cells were positively selected with
magnetic beads (MACS CD8a [Ly2] Microbeads; Miltenyi Biotec,
Bergisch-Gladbach, Germany). A total of 1 106 CD8þT cells/well
were stimulated overnight with 5 ng/mL IL-12 (see Supplementary
Materials and Methods) on 24-well plates pre-coated with anti-
CD3 and anti-CD28 antibodies at room temperature overnight
(10 mg/mL phosphate-buffered saline [PBS]; eBioscience, Frank-
furt, Germany). Fresh retrovirus supernatant was twice spinocu-
lated onto CD8þ T cells supplemented with protamine sulfate.Isolation of Liver-Associated Lymphocytes
Livers were perfused with PBS to remove circulating
leukocytes. Approximately two-thirds of the liver was mashed
with 3 mL medium through a 100-mm cell strainer. Cells that
passed were pulled through a 20-gauge needle and collected. The
procedure was repeated twice, and then mononuclear cells were
separated from other cells using a Ficoll gradient according to
the manufacturer’s instructions (Lymphoprep; PAA, Pasching,
Austria). For cell type analysis, perfused livers were digested with
4500 U collagenase (Worthington, Lakewood, NJ) for 20 minutes
at 37C. Leukocytes were purified in an 80%/40% Percoll gradient
(GE Healthcare, Uppsala, Sweden) at 1400g for 20 minutes.Flow Cytometry
Staining was performed for 30 minutes on ice in the dark
using primary antibodies (eBioscience) diluted in 0.1% bovineserum albumin/PBS. Transduction efficiency was assessed 1 day
after the second transduction by staining the CAR with anti-
human immunoglobulin G/fluorescein isothiocyanate antibody
(Sigma-Aldrich). To assess cytotoxic degranulation, anti–
CD107a-APC was added for 4 hours during incubation of T cells
on HBsAg-coated or uncoated plates. For intracellular cytokine
staining, Brefeldin A (1 mg/mL; Sigma-Aldrich) was added for 5
hours during antigen stimulation. Before phenotyping, cells
were incubated with Fc-Block for 15 minutes (BD Biosciences,
Heidelberg, Germany). After staining of dead cells with EMA
(Life Technologies) and cell surface molecules, intracellular cy-
tokines were stained using the Cytofix/Cytoperm Kit (BD Bio-
sciences). Cells were analyzed using a FACSCanto II flow
cytometer (BD Biosciences), and data were analyzed using FlowJo
9.2 software (Tree Star, Inc, Ashland, OR).Adoptive Transfer
T cells were isolated, stimulated, and transduced for
3 days before transfer. The cells were then harvested and washed
2 times with ice-cold PBS (180g, 4C, 8 minutes). CAR expression
was determined by flow cytometry. The cell number was adjusted
to 4  106 CARþ cells per animal dissolved in PBS and injected
intraperitoneally. Mice were bled at indicated time points.
Recipient mice were 16- to 24-week-old male animals. Groups of
mice were matched for age and hepatitis B e antigen titers.Statistical Analysis
Data are reported as mean values  SEM. Groups were
compared with the nonparametric Kruskal–Wallis test using
Prism 5.0 (GraphPad Software, Inc, La Jolla, CA). A P value less
than .05 was considered statistically significant. Additional
methods are described in Supplementary Materials and Methods.Results
Murine T Cells Redirected by an HBV-Specific
CAR Acquire Properties of Fully Activated
Effector T Cells
The HBV-specific chimeric antigen receptor
(S-CAR) used in this study to redirect T cells contains a
single-chain antibody fragment (scFv) that binds to the
S domain of all 3 HBV envelope proteins (S, M, and L
protein, combined as HBsAg). The scFv is linked to the
CD3z and costimulatory CD28 signaling domains
(Figure 1A), providing combined activation signals to
T cells when recognizing cell surface–bound HBsAg. The
aim of this is to overcome local hepatic coinhibitory sig-
nals.11 A human carcinoembryonic antigen (CEA)-specific
CAR served as a control for antigen-independent activa-
tion of grafted T cells. After transduction of T cells with
CARs using retroviral vectors (Figure 1B), only S-
CAR–transduced T cells produced high amounts of
interferon (IFN)-g and proliferated in an antigen-specific
manner, that is, when cocultured with HBV-replicating
human hepatoma cells but not with HBV-negative
parental cells (Figure 1C and D). We observed mobiliza-
tion of the lysosomal-associated membrane protein 1 on
binding of S-CAR–grafted T cells to plate-bound HBsAg
(Figure 1E), indicating release of cytotoxic granules.
Notably, S-CAR–redirected T cells recognized surface
Figure 1. In vitro activation of CAR-grafted primary murine T cells. (A) Schematic representation of a CAR construct consisting of a k leader (Lk),
heavy (VH) and light (VL) variable chain of an scFv, the fragment crystallizable (Fc) region of human immunoglobulin G1 (hIgG1), and transmembrane
(tm) and intracellular (ic) signaling domains of CD28 and CD3z. (B) Cell surface expression of CARs on primary murine CD4þ and CD8þ T cells
detected by anti-hIgG staining and analyzed by flow cytometry. Splenocytes were gated on CD4þ and CD8þ T cells. Percentages of cells detected in
each quadrant are given. CEA-CAR, scFv directed against CEA; S-CAR, scFv directed against the S domain of HBV envelope proteins. (C) IFN-g
production (effector to target cell ratio, n ¼ 3) and (D) proliferation of CAR-grafted T cells seeded onto HBV-replicating (right panel) and HBV-negative
(left panel) HepG2 hepatoma cells. Proliferation was assayed by flow cytometry of carboxyfluorescein succinimidyl ester (CFSE)-stained
S-CAR–grafted T cells. (E) Staining for lysosomal-associated membrane protein 1 (LAMP-1) in CAR-grafted CD8þ T cells after incubation with plate-
bound recombinant HBsAg. (F) Exposure of S-CAR–grafted T cells to recombinant HBsAg of subtype adw and ayw (n ¼ 3). All data are presented as
mean values  SEM.
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ayw (Figure 1F).Adoptively Transferred S-CAR–Grafted T Cells
Are Attracted to the Site of HBV Replication
and Proliferate in the Liver of Immune-
Competent Mice
Critical for the success of adoptive cell therapy
is the proper functionality of transferred T cells,
ensuring that these cells survive and accumulate at the
site of antigen expression.16 We compared classic IL-2
stimulation with IL-12 stimulation of T cells during
in vitro expansion and retroviral CAR transduction. IL-
12 conditioning led to a 6-fold increase in the fre-
quency of T cells within 6 days after adoptive transfer,
which was a significant improvement compared with
the established IL-2 protocol (Supplementary Figure 1A
and B). Therefore, in all further experiments, trans-
duction of CD8þ T cells was performed in the presence
of IL-12.To study targeting and antiviral properties in vivo, we
transferred CARþ CD8þ T cells (4  106) carrying the
congenic marker CD45.1 into CD45.2þ HBVtg mice. To
exclude that a mere capture of virus particles by
S-CAR–grafted T cells may contribute to or even initiate
antiviral effects, we grafted T cells with an S-decoy(D)-CAR
that uses the scFv binding site of the S-CAR but lacks
functional signaling domains (Supplementary Figure 2A
and B). Whereas numbers of T cells grafted with either
CEA-CAR or SD-CAR decreased rapidly after adoptive
transfer, S-CAR–grafted cells expanded to up to 40% of
total circulating CD8þ T cells on day 8 (Figure 2A). Because
all cells were pretreated with IL-12 in vitro, this indicated
antigen-triggered T-cell proliferation in vivo. Quantifica-
tion of transferred cells on day 12 after transfer revealed
preferential T-cell accumulation (Figure 2B) and prolifera-
tion (Supplementary Figure 2) in the liver of animals that
had received S-CAR–grafted T cells. Immunohistochem-
istry confirmed hepatic infiltration of lymphocytes
(Figure 2C), which showed cell surface expression of the
Figure 2. Survival and homing of CAR-grafted, CD45.1þ murine T cells adoptively transferred into CD45.2þ HBVtg mice. CD8þ T cells were grafted
with either S-CAR or CEA-CAR or SD-CAR for control. (A) Proportion of recovered CD45.1þ CD8þ T cells from peripheral blood of recipient mice
(mean  SEM from 5 mice per group). P ¼ .0324 comparing all 3 groups on day 8 by Kruskal–Wallis test. (B) Numbers of transferred cells per 105
mononuclear cells (MNC) in indicated compartments on day 12 after transfer. P ¼ .0122 comparing cell numbers in the livers of all 3 groups of mice
(n ¼ 5). (C) H&E staining of representative liver sections 12 days after transfer. Scale bar: panels 1–3 ¼ 500 mm; panel 4 ¼ 100 mm. Arrowheads
indicate lymphocyte infiltrations. (D) Visualization of S-CARþ T cells infiltrating the liver stained with an anti-human immunoglobulin G (hIgG) antibody.
Scale bar ¼ 20 mm. (E) Flow cytometric quantification of endogenous (CD45.1) and transferred (CD45.1þ) CD8þ T cells recovered from the liver of
individual mice. (F) Representative staining for different cell types in a liver of a mouse after treatment with S-CAR–grafted T cells. Arrows indicate
endogenous lymphocytes (CD45.2þCD3þ). Scale bar ¼ 20 mm.
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approximately one-half of the infiltrating cells and, with
the exception of one mouse, the majority of these were
transferred CD45.1þCD8þ T cells (Figure 2E and F and
Supplementary Figure 2C–E). Ki67 expression by lympho-
cytes in intrahepatic infiltrates detected in mice that had
received S-CAR–grafted T cells indicated that the adop-
tively transferred T cells proliferated at the site of HBV
replication (Supplementary Figure 2C and H). Endogenous
leukocytes present at the site of inflammation in the liver
were mainly macrophages and B cells (Figure 2F and
Supplementary Figure 2F and G). These results showed
that lymphodepletion before cell transfer is not necessary
to allow for engraftment and expansion of chimeric T cells.Transferred S-CAR–Grafted T Cells Remain
Functional Within the Hepatic
Microenvironment
The next step was to analyze whether adoptively
transferred CAR-engineered T cells executed their effector
functions within the hepatic microenvironment. We
observed liver damage indicated by serum alanine amino-
transferase (ALT) activity peaking on day 8 after transfer
and staining of apoptotic hepatocytes only in mice that
received S-CAR but not SD-CAR or CEA-CAR T cells
(Figure 3A and B). In livers of mice that received
S-CAR–grafted T cells, the immunosuppressive cytokine
IL-10 (Figure 3C) as well as the proinflammatory cytokines
IFN-g and tumor necrosis factor (TNF)-a (Figure 3D) were
Figure 3. Effector functions exerted by adoptively transferred CAR-grafted T cells. (A) ALT activity in mouse sera on days 4, 8, and 12 after transfer.
Each dot represents one mouse. P ¼ .0113 comparing ALT values of all 3 groups on day 8. (B) Representative liver sections stained for cleaved
caspase-3 on day 12 after transfer. Scale bar ¼ 200 mm. (C and D) Relative increase in hepatic cytokine expression on day 12 after transfer. Mean
values of messenger RNA levels in the CEA-CAR control group were set to 1. P ¼ .0189, P ¼ .0041, or P < .0001 for IL-10, IFN-g, or TNF-a,
respectively (n ¼ 5). (E and F) Liver-associated lymphocytes (liver) and splenocytes (spleen) were isolated on day 8 after transfer and restimulated on
HBsAg-coated plates (þHBsAg) before intracellular cytokine staining. (E) Representative flow cytometric analysis gated on endogenous cells
(CD45.1, column 1), transferred cells (CD45.1þ) without detectable S-CAR expression (column 2) or transferred cells expressing the S-CAR
(column 3). (F) Percentage of cytokine-secreting S-CARþCD8þCD45.1þ T cells in spleen and liver. Data represent mean values  SEM, n ¼ 3.
Splenocytes from each animal were restimulated in duplicate.
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associated lymphocytes with HBsAg and subsequent
intracellular cytokine staining showed that S-CAR–grafted
T cells reisolated from spleen or liver produced IFN-g and/or TNF-a in an antigen-specific fashion (Figure 3E and F).
Additional staining for PD-1 revealed that 20% of CARþ T
cells were unresponsive to antigen stimulation and
expressed the exhaustion marker PD-1. This phenotype
August 2013 T–CELL THERAPY FOR CHRONIC HEPATITIS B 461was observed less frequently when S-CAR T cells were
transferred into wild-type mice, in which antigen stimulus
was missing (Supplementary Figure 3). These results
showed that the majority of transferred S-CAR–grafted
T cells remain functional even within the immunoregula-
tory hepatic microenvironment.Adoptively Transferred T Cells Redirected by
the HBV-Specific S-CAR Exhibit a Strong
Antiviral Effect In Vivo
A profound reduction of the number of hepato-
cytes with cytoplasmic expression of HBV core protein
(Figure 4A) showed the antiviral activity of the adoptively
transferred S-CAR–grafted T cells. Moreover, the number
of virions circulating in the bloodstream rapidly decreased
100-fold (Figure 4B) and replicative forms of HBV DNA
almost completely disappeared from the liver within
12 days (Figure 4C and D). Lacking antiviral activity of
CEA-CAR and SD-CAR engineered T cells proved that
antigen recognition and T-cell activation via the S-CAR
were essential to stimulate the antiviral activity of adop-
tively transferred T cells.Treatment With S-CAR T Cells Causes Only
Minor Side EffectsFigure 4. Antiviral effect of adoptively transferred T cells grafted with
S-CAR, CEA-CAR, or SD-CAR. (A) Staining of HBV core–positive
hepatocytes in liver sections from HBVtg mice 12 days after T-cell
transfer. Scale bar ¼ 500 mm. (B) HBV viremia determined by quan-
titative polymerase chain reaction. P ¼ .0242 or P ¼ .0122 comparing
HBV DNA copies of all 3 groups on day 8 or 12, respectively. (C and
D) HBV replication in the liver on day 12 after transfer. (C) HBV DNA
copy numbers determined by quantitative polymerase chain reaction
were normalized to the single copy gene Nid2. P ¼ .009 comparing
S-CAR with CEA-CAR and SD-CAR. All data are presented as mean
values  SEM (n ¼ 5). (D) Southern blot analysis of pooled total liver
DNA. Equal amounts of liver DNA from each animal were pooled per
group and probed for HBV DNA. Relaxed circular (rc), single-stranded
(ss), and other replicative intermediate (ri) forms of HBV DNA are
indicated.
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cells did not lose weight over 34 days of treatment
(Figure 5A) and did not show any obvious signs of
distress, although serum TNF-a, IFN-g, MCP-1, IL-10,
and IL-6 levels increased significantly (Figure 5B). Levels
of immunoglobulin G1 antibodies increased, but levels
of other immunoglobulin subtypes were not altered
(Figure 5C). Twelve days after transfer, the relative
amount of CD4þ T cells and B cells decreased in the
spleen and liver while B cells and NK cells increased in
blood (Figure 5D, left panel). The relative amount of
myeloid immune cells such as inflammatory monocytes,
dendritic cells (DC), and neutrophils increased, especially
in the liver (Figure 5D, right panel). Thirty-four days after
treatment, the composition of immune cells in all an-
alyzed compartments resembled that of untreated mice
again.S-CAR–Grafted T Cells Exert Stronger
Antiviral Activity Than Natural HBV-Specific
T Cells
To compare the efficacy of S-CAR T cells with
“natural” S-specific T cells, wild-type mice were immu-
nized with recombinant HBsAg and boosted with
modified vaccinia Ankara (MVA) virus expressing S-
Protein to induce S-specific T cells for adoptive transfer
(Supplementary Figure 4). A total of 1  106 S-specific
CD8þ T cells and 1  106 and 4  106 S-CAR T cells were
injected into HBVtg mice. Most of the vaccine-induced S-
specific T cells accumulated in lymph nodes (Figure 6A),
whereas S-CAR T cells preferentially homed to the liver
(Figures 2B and 6A). ALT levels were not elevated on day 7
in animals that received 1  106 S-specific T cells. Transferof the same amount of S-CAR T cells led to an increase in
ALT activity to approximately 150 U/L. Transfer of 4 
106 S-CAR T cells led to an ALT activity of approximately
800 U/L (Figure 6B). Accordingly, S-CAR T cells reduced
cytoplasmic hepatitis B core antigen expression more
profoundly than vaccine-induced T cells (Figure 6C).
However, the effect on HBV viremia (Figure 6D) and HBV
replication in the liver (Figure 6E) was not significantly
different among the 3 treatment groups, indicating a
dominant role of noncytopathic antiviral mediators.17,18
Cytoplasmic hepatitis B core antigen and virus DNA in
the serum increased to levels before treatment, when S-
CAR T cells had almost vanished from the liver on day 34
(Figure 6C–E) and HBV replication was driven again by the
stable transgene, which cannot be eliminated. Taken
together, vaccine-induced T cells elicited their effect
Figure 5. Potential side effects of 4  106 adoptively transferred S-CAR–grafted T cells. (A) Body weight of mice relative to their individual weight
before transfer. (B) Cytokines measured in sera on different days after T-cell transfer, compared over all days (n ¼ 3–7): IL-12 (P ¼ .1163), TNF-a
(P ¼ .0049), IFN-g (P ¼ .0032), MCP-1 (P ¼ .0061), IL-10 (P ¼ .0238), or IL-6 (P ¼ .0047). (C) Immunoglobulin clonotypes in sera on different days
after T-cell transfer. P ¼ .0041 for IgG1, comparing all days (n ¼ 3–7). Data represent mean values  SEM. (D) Relative amounts of different cell types
in blood, liver, and spleen on days 12 and 34 after T-cell transfer and in untreated mice. Each symbol represents one mouse.
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killed HBV-replicating hepatocytes in addition.Discussion
Currently there is no cure for chronic hepatitis B.
Novel antiviral agents very efficiently control HBV but
cannot eliminate it. Immunotherapy using T cells that are
genetically modified to express an HBsAg-specific receptor
seems a promising addition to current antiviral therapy.
This therapy could cure chronic hepatitis B, which is a
premalignant condition, but may also be applied to treat
HBsAg-positive HCC.Our study showed that T cells redirected by an HBV-
specific CAR, when transferred into immunocompetent
mice, (1) recognize HBV envelope proteins on the surface
of HBV-replicating hepatocytes, (2) engraft and (3)
expand in vivo, (4) infiltrate the liver, and (5) effectively
control HBV replication. This new immunotherapy
approach proved safe and did not lead to excessive liver
damage after contact of T cells with circulating viral an-
tigen or to functional exhaustion of the adoptively
transferred T cells. Our results strongly suggest that
S-CAR–engineered T cells will be able to cure HBV
infection. However, this cannot be proven in the HBVtg
Figure 6. Antiviral activity of adoptively transferred S-CAR–grafted or natural S-specific T cells. CD8þ T cells were isolated and 1  106 S-specific
(2.5  107 total CD45.1þ) as well as 1  106 and 4  106 S-CAR (1.4  106 and 5.5  106 total CD45.1þ) T cells were injected into HBVtg mice.
(A) Relative amount of transferred T cells per total leukocytes in different compartments on days 12 and 34 after transfer. Data are presented as mean
values  SEM (n ¼ 3–4). (B) ALT activity in mouse sera before and 7, 12, 20, and 34 days after transfer. Each dot represents one mouse. (C) Staining
of HBV core–positive hepatocytes in liver sections fromHBVtgmice 12 and 34 days after T-cell transfer.Scale bar¼ 200 mm, inset¼ 100 mm. (D and E)
HBV viremia determined by quantitative polymerase chain reaction in (D) serum and (E) liver.
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transcribed from cccDNA but from a transgene, which
cannot be eliminated.
A prerequisite for successful adoptive T-cell therapy is
that transferred cells engraft in the recipient. Clinical trials
using adoptive T-cell therapy for malignant diseases
showed that persistence of infused cells 4 weeks after
transfer was associated with complete response to treat-
ment.11,16 In these studies, depleting lymphocytes by
chemotherapy or irradiation facilitated the engraftment of
T cells. T-cell depletion or immunosuppression, however,
is obsolete in patients with chronic hepatitis B. For tumor
therapy, it would be advantageous not to suppress the
patient’s immune system. Our study shows that successful
adoptive T-cell therapy without prior T-cell depletion or
immunosuppression is feasible. This may enable the few
endogenous antigen-specific T and B cells to restore their
antiviral or antitumoral capacity when assisted by trans-
ferred T cells.Using IL-12 instead of IL-2 for stimulation during
expansion and transduction of CD8þ T cells, we were able
to improve survival and engraftment of antigen-specific
T cells. Lower numbers of transferred T cells in control
groups suggested that engraftment was not merely an ef-
fect of in vitro IL-12 treatment but also required triggering
of the S-CAR by HBsAg. Mechanistically, IL-12 induces up-
regulation of antiapoptotic molecules such as B-cell lym-
phoma 3-encoded protein (Bcl-3)19 and cellular caspase-8
(FLICE)-like inhibitory protein (c-FLIP)20 while reducing
proapoptotic caspase activation.20,21 Moreover, IL-12 im-
proves memory cell differentiation.21,22 With IL-12 pre-
treatment, lymphodepletion before cell transfer was not
necessary to allow for engraftment and expansion of
chimeric T cells. Whether pretreatment with IL-12 will be
applicable in a clinical trial setting remains an open
question. IL-12 has been used in several clinical settings23
but currently cannot be purchased although clinical-
grade production is urgently needed.24
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therapy before adoptive T-cell therapy is that the regula-
tory function of immune cells in the liver and other organs
is preserved. In our experiments, the increasing ALT ac-
tivity in the serum selectively after transfer of S-
CAR–engineered T cells suggested that the S-CAR medi-
ated the killing of HBV-positive hepatocytes in vivo and
thus induced liver damage. Liver damage, however, was
transient. This may be explained by either increased levels
of the immunosuppressive cytokine IL-10 in the liver,
inducing an exhausted phenotype, or contraction of the
effector T-cell population after massive clonal expan-
sion,25,26 resulting in low-level cytotoxicity.27,28 Restriction
of liver damage by IL-10 was observed in several models of
immune-mediated liver damage.29,30 The cellular source of
IL-10 may be liver-resident T-helper 2 or regulatory
T cells,31 Kupffer cells,32,33 or even transferred, IL-
12–primed CD8þ T cells.34 Self-limitation of immune-
mediated damage in the liver by any of these means will
ensure organ integrity but may limit the efficiency of
immunotherapy.11 The rapid decrease of HBV replication
without severe liver disease is very likely due to the fact that
S-CAR–grafted T cells, like natural HBV-specific
T cells,18,35 control HBV in transgenic mice in a non-
cytopathic fashion via antiviral cytokines in addition to
directly killing HBV-replicating hepatocytes. This idea
is supported by the fact that ALT levels in mice treated with
1  106 T cells were much lower but the antiviral activity
was comparable to animals that received 4 times more cells.
Development of T-cell therapy for hepatitis B has been
encouraged by several observations. Control of HBV
replication is obtained after transfer of splenocytes from
immunized wild-type mice into HBVtg mice.18,27 More
importantly, cure of HBV infection in patients has been
reported after transfer of specific immunity against HBV
through allogeneic bone marrow transplantation.36,37
Bone marrow transplantation, however, is complex and
cannot be broadly applied for treatment of an infectious
disease because it requires an exact major histocompati-
bility complex match of cells derived from an immunized
donor as well as profound immunosuppression to allow
engraftment. Using the patient’s own T cells and redi-
recting them with an HBV-specific receptor seems a more
feasible approach to treat chronic hepatitis B or HBsAg-
positive HCC. CAR-grafted T cells, which function inde-
pendently of the patient’s HLA haplotype and recognize
different HBsAg subtypes, seem to be particularly suited
because they will in principle be applicable to almost all
HBV-infected patients.38
Our preclinical model has similar levels of circulating
HBsAg (approximately 1000–1200 IU/mL) as detected in
the low-replicative phase of chronic hepatitis B.39 In this
model, we observed elevation of cytokines but no severe
side effects during T-cell therapy. However, in a patient
with high replication, preexisting liver inflammation,
and tissue damage, the situation may be different. Pro-
nounced elevation of ALT levels was observed in trans-
plant recipients with cleared HBV infection,37 indicatingthat hepatocyte killing was needed for elimination. S-CAR
T cells and T cells induced by immunization of donor
mice showed comparable antiviral efficacy in our model,
but elevation of ALT levels and clearance of hepatitis B
core–positive hepatocytes indicating elimination of HBV-
positive hepatocytes was only observed after S-CAR
T-cell transfer. To avoid or reduce potential hepatotoxicity
in a clinical setting, patients will be pretreated with anti-
viral agents before T-cell transfer to reduce the amount of
HBsAg-positive hepatocytes and the grade of inflamma-
tion and increase selection pressure on the virus to mini-
mize the risk for emergence of viral variants, which could
escape CAR recognition.40 In addition, redirected T cells
can be specifically eliminated by a safeguard mechanism.
For clinical use, we have added a truncated version of the
epidermal growth factor receptor to the CAR construct,
which allows for depletion of CAR transduced cells with
the clinically approved antibody cetuximab.41
We have previously reported that human T cells that are
engrafted with the S-CAR can eliminate the nuclear persis-
tence form of HBV, the cccDNA, from HBV-infected hepa-
tocytes.12 In an alternative approach, Gehring et al42
generated 2 HBV-specific, HLA-A2–restricted T-cell re-
ceptors for grafting and showed that HBV-specific T cells
generated from peripheral blood mononuclear cells of pa-
tients with chronic HBV and HBV-related HCC became
multifunctional and capable of recognizingHBV-replicating
hepatoma cells and HCC tumor cells expressing viral anti-
gens from naturally integrated HBV DNA. We also have
established a series of such recombinant T-cell receptors of
diverse receptor avidity (unpublished data; October 2011)
and are currently comparing these with respect to optimal
functionality.
The in vivo study presented here showed that
S-CAR–grafted T cells (although vast amounts of subviral
particles are present in the blood of HBVtg mice) infiltrate
the liver, remain functional, and lead to a profound reduc-
tion of viral load. From the data obtained, we conclude that
immunotherapy with S-CAR–grafted T cells is a feasible and
promising approach to treat chronic HBV infection,
providing proof of concept for further translation of
adoptiveT-cell therapy for chronic hepatitis B into the clinic.Supplementary Material
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